Production (Stage)
Bicycle Therapeutics plc
BCYC
$8.05
-$0.05-0.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | 169.07% | 38.57% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 169.07% | 38.57% | |||
| Cost of Revenue | 194.16% | -233.24% | |||
| Gross Profit | -169.31% | 258.80% | |||
| SG&A Expenses | 49.75% | -26.71% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.34% | 7.29% | |||
| Operating Income | -3.76% | -5.98% | |||
| Income Before Tax | -16.82% | 2.42% | |||
| Income Tax Expenses | -0.46% | 68.62% | |||
| Earnings from Continuing Operations | -17.16% | -2.07% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -17.16% | -2.07% | |||
| EBIT | -3.76% | -5.98% | |||
| EBITDA | -3.96% | -6.95% | |||
| EPS Basic | -16.93% | -1.97% | |||
| Normalized Basic EPS | -7.51% | -7.62% | |||
| EPS Diluted | -16.93% | -1.97% | |||
| Normalized Diluted EPS | -7.51% | -7.62% | |||
| Average Basic Shares Outstanding | 0.21% | 0.09% | |||
| Average Diluted Shares Outstanding | 0.21% | 0.09% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||